Description
Ramucirumab, marketed under the brand name Cyramza, It is an prescription medication that has been approved by the FDA for multiple uses, including:
Metastatic non-small cell lung cancer (NSCLC): On May 29, 2020, the FDA approved ramucirumab in combination with erlotinib as a first-line treatment for metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
Hepatocellular carcinoma (HCC): On May 10, 2019, the FDA approved ramucirumab as a single agent for HCC.
Metastatic NSCLC after platinum-based chemotherapy: On December 12, 2014, the FDA approved ramucirumab in combination with docetaxel for patients with metastatic NSCLC whose tumor progressed during or after treatment with platinum-based chemotherapy.
What is Cyramza (Ramucirumab) ?
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors.
On 21 April 2014, the US Food and Drug Administration (FDA) approved ramucirumab as a single-agent treatment for advanced gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy.
Ramucirumab has also been studied in combination with paclitaxel (a type of chemotherapy) and received additional FDA approval on 5 November 2014 as a treatment for people with advanced gastric cancer or GEJ adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-based chemotherapy.
On 12 December 2014, the FDA approved ramucirumab in combination with docetaxel for treatment of metastatic non-small-cell lung carcinoma (NSCLC) with disease progression during or after first-line platinum-containing chemotherapy.
On 24 April 2015, ramucirumab was approved by FDA for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and fluoropyrimidine.
On 10 May 2019, ramucirumab was approved by FDA as a single agent treatment for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of > 400 ng/mL and have been previously treated with sorafenib.
How to order approved “Cyramza (Ramucirumab) for Injection” Medicine?
Cyramza (Ramucirumab) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing Cyramza and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
